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Correspondence Troponin Release Overestimates Infarct Sizein Presence of Left Ventricular HypertrophyTo the Editor: After an acute myocardial infarction (AMI), infarct
size quantification is of clinical importance because it correlates
with postinfarction mortality and morbidity (1). The gold standard
in vivo techniques for infarct size quantification are magnetic
resonance imaging and single-photon emission computed tomog-
raphy; however, these methods are not universally available.
Systemic determination of both peak and area under the curve of
circulating concentrations of creatine kinase (CK) and troponins
positively correlate with infarct size as measured by using the gold
standard techniques (2). It has also been demonstrated that single
ime-point troponin concentration displays a strong correlation with
nfarct size (2,3). Circulating levels of necrosis biomarkers not only
orrelate with infarct size and ejection fraction but also predict clinical
utcomes after a ST-segment elevation myocardial infarction
STEMI) (2). As a result, infarct size is frequently assessed by using
ystemic biomarkers release, both in daily practice and in clinical trials.
Because the heart is a postmitotic organ, left ventricular hypertro-
hy (LVH) is attained by hypertrophy of pre-existing myocytes. Such
ypertrophy is encompassed by an increase of contractile units and
heir proteins (including troponin). In fact, it has been shown that,
ompared with normal cardiomyocytes, hypertrophied cardiomyo-
ytes display an increased troponin concentration (4) but unchanged
total CK concentration (5). Therefore, we hypothesized that upon an
AMI, the systemic release of troponins will be disproportionately
higher than that of CK in patients with LVH. As a consequence, the
prediction of infarct size based on the circulating levels of troponin
might be confounded by the presence of LVH.
To test this hypothesis, data from 937 consecutive STEMI
patients admitted to our coronary care unit between 2004 and 2009
were analyzed. For every patient, total CK (assessed by using a
standard enzymatic method on an Olympus AU2700 analyzer
[Beckman Coulter Clinical Diagnostics, Nyon, Switzerland]) and
troponin I (chemoluminescence immunoassay on a Dimension
Xpand system [Siemens Healthcare Diagnostics, Deerfield, Illi-
nois]) levels were measured on admission and then every 4 h to
identify peak enzyme release. A standard echocardiogram was
performed 3 to 5 days post-STEMI, and patients were classified
into 4 categories according to left ventricle thickness following
standard echocardiography recommendations: normal left ventricle
thickness and mild, moderate, and severe LVH.
We used multivariable linear regression analysis to estimate the
differences of troponin I release between LVH categories adjusted by
total CK release and other potential confounders. To avoid potential
bias, 56 patients with 1 of the following conditions were excluded
from the analysis: mechanical complications, cardiogenic shock,
asymmetric hypertrophy, skeletal muscle disease, history of STEMI,
and those not revascularized by any means. These patients were
excluded because the increase in circulating CK could be affected by
noncardiac CK release. A total of 377 patients with missing values in
any of the independent variables considered in the multivariableadjustment were further excluded for statistical purposes. Therefore,
the final study population comprised 504 patients. Given the low
number of patients with severe LVH (n  5), these were merged
within the moderate LVH groups for analytical purposes.
Statistical analyses were performed by using the open-source
statistical scripting language R (version 2.3.0., R Foundation for
Statistical Computing, Vienna, Austria). The distribution of peak
troponin I and CK levels were positively skewed, and a logarithmic
transformation was performed. As a consequence, data of bio-
markers are expressed in terms of geometric means. The ratio of
geometric means of biomarkers release comparing patients with mild
LVH and moderate/severe LVH versus patients with no LVH were
estimated by using a multivariable linear regression model adjusted for
the concentration of CK (or troponin I), sex, age, hypertension,
diabetes, ejection fraction, time to reperfusion, ventricular fibrillation,
AMI localization, Killip-Kimball class, and beta-blocker treatment.
Standard diagnostic checks on the residuals from the fitted models
showed no evidence of any failure of the assumption of normality and
homogeneity of the residual variance.
Clinical variables from patients according to LVH categories are
shown in Figure 1A. Distribution of excluded patients across LVH
categories was similar to that of the actual study population. Peak
CK values did not differ among the LVH categories. Conversely,
significant differences in troponin I levels were found across LVH
categories: troponin I concentrations were significantly higher in
patients with mild and moderate/severe LVH compared with
patients with no hypertrophy: troponin I was 13.7% greater in
patients with mild LVH versus patients with no hypertrophy (95%
confidence interval: 2.5 to 26.1; p  0.02) and 17.8% in patients
showing moderate/severe LVH versus patients with no hypertro-
phy (95% confidence interval: 3.3 to 34; p  0.02) (Fig. 1).
Time-to-peak of biomarkers release was similar in the 3 different
LVH categories.
The value of biomarkers release to estimate infarct size is
supported by several lines of evidence. Chia et al. (2) showed that,
in STEMI patients, single time-point, peak, and area under the
curve of CK (total and fractions) and troponins release significantly
correlate with infarct size and ejection fraction, measured by using
single-photon emission computed tomography. Intriguingly, al-
though many reports have documented that troponin release
correlates better with infarct size assessed by using gold standards,
some authors have observed that, despite being a noncardioselec-
tive biomarker, total CK peak values better correlate with infarct
size measured by using magnetic resonance imaging than troponin
values (6). After our findings, it may be speculated that LVH can
act as a confounding factor when troponins are used as infarct size
estimators. Here we show that STEMI patients with LVH had
significant greater troponin I release than patients with normal left
ventricle thickness at a given CK value. According to the incidence
of LVH in our nonselected STEMI population and others,
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August 14, 2012:640–4myocardial infarction size calculated according to peak troponin
release can be overestimated in 30% of patients, something that
should be taken into consideration in studies evaluating the effect
of therapies in infarct size. In the presence of moderate/severe
LVH, the discrepancy between total CK and troponin I can be as
much as 34%. Such a variation in infarct size is of great biological
impact in clinical trials testing the effect of cardioprotective interven-
tions, and therefore the current results have a significant impact.
Given that LVH has been shown to be associated with an increase in
cardiomyocyte B-chain protein (5), the current data should not be
sed to infer that CK–myocardial band will be equally dissociated
rom troponin values.
Although future prospective examinations using gold standard
echniques should be performed to confirm our retrospective
nalysis, the current results may have significant implications
ecause troponin I release seems to overestimate infarct size in
atients with LVH.
To the best of our knowledge, this is the first time that a
ifferent pattern of CK and troponin I enzyme increase has been
hown in STEMI patients with LVH.
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